Docetaxel liposomal - Sun Pharma Advanced Research Company

Drug Profile

Docetaxel liposomal - Sun Pharma Advanced Research Company

Alternative Names: DICN; Docetaxel injection concentrate for nanodispersion; Docetaxel nanodispersion - Sun Pharma Advanced Research Company; Liposome-encapsulated docetaxel - Sun Pharma Advanced Research Company

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 30 Jun 2012 Phase-I clinical trials in Non-small cell lung cancer in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top